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Abstract 
DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape 
have been recognized as a hallmark of cancer. However, the role of DNA methylation in 
epithelial ovarian cancer (EOC) remains unclear. In this study, high density genetic and DNA 
methylation data in white blood cells from the Framingham Heart Study (N=1,595) were used to 
build genetic models to predict DNA methylation levels. These prediction models were then 
applied to the summary statistics of a genome-wide association study (GWAS) of ovarian cancer 
including 22,406 EOC cases and 40,941 controls to investigate genetically predicted DNA 
methylation levels in association with EOC risk. Among 62,938 CpG sites investigated, 
genetically predicted methylation levels at 89 CpG were significantly associated with EOC risk 
at a Bonferroni-corrected threshold of P<7.94×10
-7
. Of them, 87 were located at GWAS-
identified EOC susceptibility regions and two resided in a genomic region not previously 
reported to be associated with EOC risk. Integrative analyses of genetic, methylation, and gene 
expression data identified consistent directions of associations across 12 CpG, five genes, and 
EOC risk, suggesting that methylation at these 12 CpG may influence EOC risk by regulating 
expression of these five genes, namely MAPT, HOXB3, ABHD8, ARHGAP27 and SKAP1. We 
identified novel DNA methylation markers associated with EOC risk and propose that 
methylation at multiple CpG may affect EOC risk via regulation of gene expression. 
Significance: Identification of novel DNA methylation markers associated with EOC risk 
suggests that methylation at multiple CpG may affect EOC risk through regulation of gene 
expression.  
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Introduction 
Ovarian cancer is one of the most deadly cancers among women in the United States (1) and 
around the world (2). Approximately 90% of ovarian neoplasms are epithelial ovarian cancer 
(EOC) (1), a heterogeneous disease that can be categorized into five major histotypes (1). 
Genetic factors have an important impact on EOC etiology. Large-scale genome-wide 
association studies (GWAS) have identified 34 common risk loci for EOC to date (3). Of these, 
27 are specific to the most common histotype, serous EOC (3). However, known loci are 
estimated to account for only a small proportion (~6.4%) of overall EOC risk (3). In addition, 
causal genes at most loci and the underlying pathogenic mechanisms are yet to be identified. 
 
In addition to genetic susceptibility, cancer initiation and progression are also influenced by 
epigenetics (4). The most extensively studied epigenetic marker is DNA methylation, which 
regulates chromatin structure (5) and gene expression (6). DNA methylation patterns are 
generally programmed during normal development (7). Abnormal methylation has been 
observed in multiple malignancies, including EOC (8,9). Studies have identified multiple DNA 
methylation markers in tumor tissue samples as prognostic biomarkers for EOC (10,11). Several 
studies have also investigated the potential of DNA methylation from white blood cells to be 
early detection biomarkers for EOC and identified nearly 100 candidate CpGs for EOC risk (12-
15). To date, only two CpGs, cg10061138 and cg10636246, were consistently observed across 
different studies (12-15). The lack of consistent findings may reflect the small sample sizes of 
prior studies (200-400 cases), an inadequate consideration of potential confounders and reverse 
causation.  
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DNA methylation is impacted by both environmental factors and genetic factors (6). High-
throughput methylome profiling in both twin and familial studies has shown that methylation 
levels for a large number of CpGs are heritable (16,17). Furthermore, several studies (18,19) 
have revealed a large number of methylation quantitative trait loci (meQTL) in white blood cells. 
These results suggest that DNA methylation levels could be partially predicted by genetic 
variants. Indeed, meQTL single nucleotide polymorphisms (SNPs) appear to predict DNA 
methylation levels in white blood cells and the predicted methylation levels associated with 
disease risk (20,21). However, these studies only used single meQTL SNPs to predict 
methylation levels for each CpG site. The prediction accuracy is low because meQTL SNPs 
explain only a small proportion of variance. In the present study, we used a novel approach to 
overcome this limitation by building and validating statistical models to predict methylation 
levels based on multiple genetic variants in reference datasets. The prediction models were then 
applied to genetic data from 22,406 cases and 40,941 controls to test the hypothesis that 
genetically predicted DNA methylation is associated with EOC risk. This approach could 
overcome the selection bias and reverse causation in conventional epidemiological studies of 
DNA methylation and disease because alleles are randomly assigned during gamete formation. 
 
Methods 
Building DNA methylation prediction models using data from the Framingham Heart 
Study (FHS) 
Genome-wide DNA methylation and genotype data from white blood cell samples from 
individuals in the FHS Offspring Cohort were obtained from dbGaP (accession numbers 
phs000724 and phs000342, respectively). Detailed descriptions of the FHS Offspring Cohort 
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have been previously reported (22). Genotyping was conducted using the Affymetrix 500K 
mapping array and imputation was performed with the1000 Genome Phase I (version 3) data as 
reference. Only SNPs with a minor allele frequency (MAF) of ≥0.05 and an imputation quality 
(R
2
) of ≥0.80 were used to build prediction models. Genome-wide DNA methylation profiling 
was generated using the Illumina HumanMethylation450 BeadChip. We used the R package 
“minfi” (23) to filter low quality methylation probes, evaluate cell type composition for each 
sample and estimate methylation beta-values. Methylation data were then quantile-normalized 
across samples, rank-normalized to remove potential outliers, and then regressed on covariates 
including age, sex, cell type composition and top ten principal components (PCs) to eliminate 
potential experimental confounders and population structure. Finally, 1,595 unrelated individuals 
of European descent (883 females and 712 males, mean ± SD of age: 66.3 ± 9.0) with both 
genetic and DNA methylation data were included in prediction model building.  
 
Using the elastic net method (α=0.50) implemented in the R package “glmnet” (24), we built a 
statistical model to predict methylation levels for each CpG site using the SNPs within its 2 
megabase (Mb) flanking region. For each model, we performed tenfold cross-validation as 
internal validation and calculated the squared value of the correlation coefficient between 
measured and predicted methylation levels, i.e. RFHS
2
, to estimate prediction performance. 
 
Evaluation of model performance using data from the Women’s Health Initiative (WHI) 
Using data from white blood cell samples from 883 independent healthy women of European 
descent from the WHI, we evaluated the performance of the established genetic prediction 
models. Data from the WHI samples were obtained from dbGaP (accession numbers phs001335, 
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phs000675 and phs000315). Genotyping was conducted using the HumanOmniExpress and 
HumanOmni1-Quad array. The data were quality control (QC)-ed and imputed using similar 
criteria and procedures as those described for the FHS data. The Illumina HumanMethylation450 
BeadChip was used to profile DNA methylation and the data were then processed using the same 
pipeline as that for the FHS data. The prediction models established in FHS were applied to the 
genetic data in WHI to predict methylation levels at each CpG site for each sample. Then, the 
predicted and measured methylation levels for each CpG site were compared by estimating the 
squared value of the Spearman correlation coefficient, i.e. RWHI
2
. 
 
We used the following criteria to select prediction models for association analyses: 1) a 
prediction RFHS
2
 of ≥0.01 (correlation between measured and predicted methylation levels of 
≥0.10) in the FHS; 2) a RWHI
2 of ≥0.01 in the WHI; and 3) methylation probes on the 
HumanMethylation450K BeadChip not overlapping with any SNP included in the dbSNP 
database (25) (Build 151), considering that SNPs on the probes may have a potential impact on 
the methylation level estimation (19). In total, models for 63,000 CpGs met these requirements 
and were included in the downstream association analyses for EOC risk.  
 
Association between genetically predicted DNA methylation and EOC risk 
MetaXcan (26) was used to estimate the associations between genetically predicted methylation 
levels and EOC risk. The methodology of MetaXcan has been described elsewhere (26,27). 
Briefly, the following formula was used to evaluate the association Z-score: 
𝑍𝑚 ≈  ∑ 𝑤𝑠𝑚𝑠∈Model𝑚
?̂?𝑠
?̂?𝑚
 
?̂?𝑠
se(?̂?𝑠)
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In the formula, 𝑤𝑠𝑚 represents the weight of SNP 𝑠 on the methylation level of the CpG site 𝑚, 
estimated by the prediction model. ?̂?𝑠 and ?̂?𝑚 are the evaluated variances of SNP 𝑠 and the 
predicted methylation level at CpG site 𝑚, respectively. ?̂?𝑠 and se(?̂?𝑠) represent the beta 
coefficient and standard error of SNP 𝑠 on EOC risk, respectively. For this study, the correlations 
between predicting SNPs for all CpGs were evaluated using the data from European participants 
in the 1000 Genomes Project Phase 3. 
 
Beta coefficient ?̂?𝑠 and standard error se(?̂?𝑠) for the association between SNP s and EOC risk 
were obtained from the Ovarian Cancer Association Consortium (OCAC), which includes 
22,406 EOC cases and 40,941 controls of European ancestry (3). Details of this consortium have 
been described elsewhere (3). For EOC patients, some may have had neo-adj chemotherapy 
before surgery. They were not included in sub-type analyses but included in the analyses for 
overall EOC risk (3). Cases were classified as one of five histotypes: high-grade serous 
(N=13,037), endometrioid (N=2,810), mucinous invasive (N=1,417), clear cell (N=1,366) or 
low-grade serous (N=1,012). In addition, there were 2,764 EOC cases that could not be 
categorized into any histotypes. Genotyping was conducted using OncoArray and other GWAS 
arrays, followed by imputation, with the 1000 Genomes Project Phase 3 as reference. 
Association analyses were conducted within each dataset (different GWAS arrays) and the 
results were combined by a fixed-effect inverse-variance meta-analysis. Among the 751,157 
SNPs included in the prediction models for 63,000 CpGs, summary statistics for associations 
between 751,031 (99.98%) of these SNPs and EOC risk were available from the OCAC. A total 
of 62,938 CpGs, corresponding to these 751,031 SNPs, were included in the final analyses. This 
study was approved by the OCAC Data Access Coordination Committee. 
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For risk analyses in OCAC, we used a Bonferroni-corrected threshold of P<7.94×10
-7
 
(0.05/62,938) for statistical significance in assessing the association between each of the 62,938 
CpGs and EOC risk. Associations of predicted methylation and EOC risk identified in the OCAC 
data were further evaluated using the summary statistics of two GWAS studies of ovarian cancer 
in the UK Biobank (28). However, the sample size of the EOC cases is very small, with only 440 
histologically diagnosed and 579 self-reported ovarian cancer cases among nearly 337,000 
unrelated individuals of European descent. GWAS analyses were conducted using a linear 
regression model. The summary statistics data are available at 
https://sites.google.com/broadinstitute.org/ukbbgwasresults/home.  
 
We estimated whether the identified associations of predicted methylation with EOC risk were 
independent of GWAS-identified EOC susceptibility variants. For each SNP included in the 
prediction model, we used GCTA-COJO (29) to evaluate the ?̂?𝑠 and se(?̂?𝑠) with EOC risk after 
adjusting for the GWAS-identified variants for EOC. Then we re-conducted the MetaXcan 
analyses to investigate the associations of the predicted methylation levels with EOC risk 
conditioning on the GWAS-identified EOC risk variants. We also performed stratification 
analyses by six EOC histotypes and estimated the heterogeneity across histotype groups by using 
Cochran’s Q test. 
 
Functional annotation of methylation markers 
Using ANNOVAR (30), all 62,938 investigated CpGs were classified into 11 functional 
categories: upstream, transcription start site upstream 1500bp (TSS1500), TSS200, 5’-
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untranslated region (UTR), exonic, intronic, 3’-UTR, downstream, intergenic, non-coding RNA 
(ncRNA) exonic and ncRNA intronic.  
 
Correlation analyses of DNA methylation with gene expression in white blood cells 
For those 89 CpGs with predicted methylation levels associated with EOC risk, we investigated 
those methylation levels in relation to the expression levels of genes flanking these CpGs. 
Individual-level DNA methylation and gene expression data of white blood cell samples from 
the FHS Offspring Cohort were accessed from dbGaP (accession numbers phs000724 and 
phs000363). The details of the Offspring Cohort of the FHS, the DNA methylation data and gene 
expression data have been described previously (22,31). In total, 1,367 unrelated participants 
with both methylation and gene expression data were included in correlation analyses. A 
threshold of P<0.05 was used to determine a nominally-significant correlation between 
methylation level and gene expression level. In addition, using data from the FHS, we 
investigated whether the methylation of those 89 EOC-associated-CpGs could regulate the 
expression of 19 homologous recombination (HR) genes (32,33). 
  
Association analyses of genetically predicted gene expression with EOC risk  
For genes with expression levels nominally correlated with methylation levels of CpGs that were 
associated with EOC, we investigated whether genetically predicted gene expression levels were 
associated with EOC risk following methods described elsewhere (27). Briefly, genome-wide 
genetic and gene expression data from 6,124 different tissue samples (donated by 369 
participants of European ancestry) included in the Genotype-Tissue Expression (GTEx) release 6 
(34) were used to build genetic models for gene expression prediction by following the elastic 
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net method (27). The models were then applied to the OCAC data to estimate the associations 
between genetically predicted gene expression levels and EOC risk by using MetaXcan (26). We 
used Bonferroni correction to declare statistically significant associations. 
 
Consistent directions of associations across methylation, gene expression and EOC risk 
To infer potential mechanisms underlying the identified associations between DNA methylation 
and EOC risk, we conducted integrative analyses of the association results between predicted 
CpG methylation and EOC risk, correlations between CpG methylation and gene expression, and 
associations between gene expression and EOC risk. First, we examined whether the association 
directions among DNA methylation, gene expression and EOC risk were consistent. Then, we 
evaluated whether genetically predicted methylation might mediate associations between gene 
expression and EOC risk. Briefly, for each gene we used GCTA-COJO (35) to generate modified 
summary statistics of associations between SNPs in its expression prediction models and EOC 
risk after adjusting for SNPs included in the methylation prediction model of its corresponding 
CpG site. Finally, the prediction models of each gene were applied to the updated summary 
statistics using MetaXcan (26) to estimate the association between genetically predicted gene 
expression and EOC risk conditioning on the effects of the genetically predicted methylation 
level at each corresponding CpG site. 
 
Results 
DNA methylation prediction models 
Figure 1 presents the overall workflow of this study. Data from the FHS Offspring Cohort were 
used to create methylation prediction models for 223,959 CpGs. Of these, 81,361 showed a 
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prediction performance (RFHS
2) of ≥0.01, representing at least a 10% correlation between 
predicted and measured methylation levels. For these 81,361 CpGs, the number of SNPs in 
prediction models ranged from 1 to 276, with a median of 25. Applying these 81,361 models to 
genetic data from the WHI, 70,269 (86.4%) models showed a correlation coefficient between 
predicted and measured methylation levels (RWHI) of >10%. Among these 70,269 CpGs, 
methylation probes of 7,269 on the HumanMethylation450 BeadChip overlapped with SNPs, 
which may have affected the estimation of the methylation levels (19). Hence, these CpGs were 
excluded. The remaining 63,000 CpGs were included in the downstream analyses. 
 
Associations of genetically predicted DNA methylation with EOC risk 
The prediction models were applied to the data from a GWAS of 22,406 EOC cases and 40,941 
controls included in OCAC. Summary statistics of associations between 751,031 of the 751,157 
SNPs, corresponding to 62,938 of the 63,000 CpGs, and EOC risk were available in OCAC. For 
these 62,938 CpGs, a high correlation of prediction performance between models based on FHS 
(RFHS
2
) and WHI (RWHI
2
) data was observed, with a Pearson correlation coefficient of 0.95. This 
indicates that for each of these CpGs, a same set of predicting SNPs could predict a very similar 
methylation level, using either FHS or WHI data. 
 
For most of these 62,938 CpGs, a large majority of predicting SNPs were available in OCAC 
(e.g., for 94% of the investigated CpGs, ≥95% of the SNPs in prediction models were available 
in OCAC). Supplementary Figure 1 is the Manhattan plot presenting the associations between 
genetically predicted methylation levels and EOC risk. Among the 62,938 CpGs, 89 were 
significantly associated with EOC risk at a Bonferroni-corrected threshold of P<7.94×10
-7
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(Table 1 and 2, Supplementary Table 1). Among these 89 CpGs, a higher predicted 
methylation level was associated with an increased risk of EOC at 48 CpGs, and with a 
decreased EOC risk in the other 41 CpGs. These indicates that the methylation levels were 
predicted to be higher for 48 CpGs and lower for 41 CpGs among EOC cases than among 
controls. For these 89 CpGs, we also re-built the prediction models only using data from females 
(N=833) in FHS. A very high correlation was observed, with a Pearson correlation coefficient of 
0.99, between the prediction performance R
2
 values, based on data of all FHS participants 
(N=1,595) and those based on females only data (N=833). In the UK Biobank data, consistent 
associations were observed for 23 CpGs, including 12 at P<0.05, and 11 additional CpGs at 
P<0.10 (Supplementary Table 2). This relatively low replication rate is not unexpected, 
considering the very limited statistical power of the UK Biobank data because of a very small 
number of cases (N=400~600).  
 
Among the 89 CpGs that were associated with EOC, two reside in a genomic region on 
chromosome 7 that has not yet been reported for EOC risk (500Kb away from any GWAS-
identified EOC susceptibility variants) (Table 1). Given that there are no risk variants identified 
by previous GWAS on this chromosome, associations with EOC risk conditioning on 
proximally-located risk variants could not be conducted. Among the remaining 87 CpGs located 
in nine previously-identified EOC risk loci, no associations remained significant after an 
adjustment for all risk SNPs in the corresponding loci. This suggests that the associations of 
these 87 CpGs with EOC risk were all driven by known EOC risk SNPs in these loci (Table 2 
and Supplementary Table 1).  
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Stratification analyses by EOC histotypes revealed that all 89 CpGs were associated with both 
serous ovarian cancer and high-grade serous ovarian cancer. Fewer CpGs were associated with 
the other histotypes, including endometrioid ovarian cancer (cg25137403, cg14454907 and 
cg25708328), mucinous ovarian cancer (cg25137403, cg14454907, cg10086659 and 
cg25708328) and low-grade serous ovarian cancer (cg01572694) (Supplementary Tables 3-4). 
Fourteen of these 89 CpGs showed more significant associations with the serous and the high-
grade serous ovarian cancers than with other histotypes, with a heterogeneity test P<5.62×10
-4
, a 
Bonferroni-corrected threshold (0.05/89) (Supplementary Table 3). Among these 89 CpGs, a 
significant correlation of methylation and gene expression was identified for 91 CpG-HR gene 
pairs, including 22 CpGs and 11 HR genes, at a Bonferroni-corrected threshold of P<2.96×10
-5
 
(0.05/1,691) (Supplementary Table 5). Interestingly, methylation levels of three CpGs, i.e. 
cg13568213 (9q34.2), cg10900703 (10p12.31) and cg23659289 (17q21.31) showed a strong 
correlation with the expression level of the ATM gene. 
 
DNA methylation affecting EOC risk through regulating expression of a neighbor gene 
For those 89 CpGs with predicted methylation levels associated with EOC risk, we conducted 
correlation analyses with gene expressions for 63 pairs of CpG-gene, including 58 CpGs with 21 
flanking genes that were annotated by ANNOVAR (30). Nominally significant correlations were 
observed for 26 CpG-gene pairs, including 26 CpGs and 12 genes, at P<0.05 (Table 3, 
Supplementary Table 6). Among them, the most significant correlation was observed between 
the increased methylation at the CpG cg19139618, located in the promoter region of the SKAP1 
gene, and the expression level of SKAP1, with a P value of 2.98×10
-15
 (Table 3). In addition, 
increased methylation levels at two CpGs, cg10900703 and cg04231319, located in the introns of 
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the MLLT10 gene, were significantly correlated with an increased expression of MLLT10, with P 
values of 2.79×10
-11
 and 1.36×10
-5
, respectively. For the two CpGs located in a putative novel 
locus, a higher methylation level for one of them, cg03634833, was correlated with a lower 
expression of the ADAP1 gene in this locus, with a P value of 2.99×10
-3
 (Supplementary Table 
6). As expected, methylation levels at CpGs located in promoter regions (TSS1500 and TSS200) 
were more likely to be negatively correlated with expressions of proximal genes. Nearly all 
CpGs located in downstream or in 3’UTR showed a negative regulatory effect on expression of 
neighbor genes. For CpGs residing in intronic regions, both positive and negative correlations 
were observed.  
 
For the 12 genes with expression levels correlated with DNA methylation, expression prediction 
models were built for seven, with a prediction performance (R
2
) of ≥0.01, using GTEx data. 
Applying these seven models to the OCAC data, genetically predicted expression levels of three 
genes, namely MAPT, HOXB3 and ABHD8, were significantly associated with EOC risk after 
Bonferroni correction (Table 4). At 17q21.31 and 17q21.32, higher predicted expression levels 
of MAPT and HOXB3 were associated with a decreased EOC risk, with P values of 3.74×10
-4
 
and 2.00×10
-7
, respectively. After adjusting for established EOC risk SNPs, the associations 
between these two genes and EOC risk disappeared. At 19p13.11, an increased predicted 
expression level for ABHD8 was associated with an increased EOC risk, with a P value of 
9.93×10
-6
.  Conditioning on the EOC risk SNP in this locus, the association disappeared as well 
(Table 4). Of the five genes without prediction models, two were previously reported to be 
associated with EOC susceptibility, including SKAP1 (36) and ARHGAP27 (37). 
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We integrated the results for the associations between DNA methylation and EOC risk, the 
correlation between DNA methylation and gene expression, and the association between gene 
expression and EOC risk. We identified consistent directions of associations across seven CpGs, 
including cg18878992, cg00480298, cg07368061, cg01572694, cg14285150, cg24672833 and 
cg17941109, three genes, including MAPT, HOXB3 and ABHD8, and EOC risk (Table 5). The 
mechanism potentially underlying the associations of methylation at these seven CpGs and EOC 
risk may be their regulatory function on expression of these three genes. Among them, increased 
methylation at the CpG site cg14285150 was associated with an increased HOXB3 expression 
(P=8.44×10
-5
) and decreased EOC risk (P=5.53×10
-8
). As expected, an increased expression of 
HOXB3 was associated with a decreased EOC risk (P=2.00×10
-7
). Conditioning on SNPs 
included in the methylation prediction model for cg14285150, the association of HOXB3 
expression and EOC risk disappeared (P=0.51) (Table 5).  
 
Expression prediction models could not be built for SKAP1 at 17q21.32 and ARHGAP27 at 
17q21.31 in the present study. Hence, these two genes could not be investigated in association 
with EOC risk. However, higher expression levels of these two genes have been previously 
reported to be associated with an increased risk of EOC (36,37). This is expected, based on the 
association results of DNA methylation with EOC risk and DNA methylation with gene 
expression (Table 5). For example, a higher methylation at cg19139618 was associated with a 
lower expression of SKAP1 (P=2.98×10
-15
) and lower EOC risk (P=7.08×10
-7
). Hence, the 
potential mechanism underlying the association between cg19139618 and EOC risk may be the 
down-regulation effects on SKAP1 expression (Table 5).  
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Discussion 
In this large study, we identified 89 CpGs that were significantly associated with EOC risk, 
including two CpGs located in a novel genomic region that have not yet been reported as a 
susceptibility locus for EOC. Integrating genetic, methylation and gene expression data 
suggested that methylation at 12 of 89 CpGs may exert their impacts on EOC risk through 
regulating the expression of five genes. These results provide new insights into the regulatory 
pathways that connect genetics, epigenetics, gene expression and EOC risk. 
 
We identified two methylation markers, cg18139273 and cg03634833, located at 7p22.3, a novel 
genomic region that had not been reported as a risk locus for EOC. Both CpGs reside in the 3
rd
 
intron of the 1
st
 transcript of the ADAP1 gene, which encodes an ADP-ribosylation factor 
GTPase-activating protein (ArfGAP) with dual PH domains 1. ADAP1 functions as a scaffolding 
protein in several signal transduction pathways. It is highly expressed in neurons, where it has 
roles in neuronal differentiation and neurodegeneration (38). This gene has also been reported to 
be involved in mitochondrial function (39), and is a target of the ErbB4 transcription factor in 
mammary epithelial cells (40). In the present study, we found that a higher methylation level at 
cg03634833 was significantly correlated with a lower ADAP1 expression, which was associated 
with a non-significantly decreased EOC risk. Thus, methylation at cg03634833 might be 
associated with EOC risk through a regulatory function on ADAP1 expression, or through other 
unidentified mechanisms.  
 
Integrating the results of the associations between DNA methylation and EOC risk, the 
correlation between DNA methylation and gene expression, and the association between gene 
Research. 
on January 14, 2019. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 17, 2018; DOI: 10.1158/0008-5472.CAN-18-2726 
Page 33 of 48 
 
expression and EOC risk, we observed consistent directions of associations across 12 CpGs, five 
genes and EOC risk. For the MAPT gene (17q21.31), an increased methylation at two CpGs 
located in its exons, cg18878992 and cg00480298, were associated with a decreased MAPT 
expression and increased EOC risk. For the other CpG site, cg07368061, located at the 1
st
 intron 
of MAPT, its increased methylation was associated with a higher MAPT expression and lower 
EOC risk. As expected, an increased MAPT expression was associated with decreased EOC risk. 
The MAPT gene has been linked to multiple neurodegenerative disorders, including progressive 
supranuclear palsy (41), Parkinson’s disease (42,43) and Alzheimer's disease (42). In addition, a 
higher expression of a MAPT protein isoform (<70 kDa) was correlated with a lower sensitivity 
to taxanes in breast cancer cells (44). Methylation of the microRNA (miRNA) miR-34c-5p was 
shown to regulate the MAPT expression, which was related to paclitaxel-resistance in gastric 
cancer cells (45).  
 
Increased methylation of three CpGs in the 1
st
 intron of the HOXB3 gene (17q21.32), 
cg01572694, cg14285150 and cg24672833, were associated with an increased expression of 
HOXB3 and decreased EOC risk. As expected, an increased HOXB3 expression was associated 
with decreased EOC risk. A previous study reported that the expression of HOXB3 was up-
regulated in EOC cell lines compared with normal samples (46). However, this study only 
included five patients and the results have not been replicated by an independent study. On the 
other side, we investigated the genetically predicted methylation levels in DNA from white blood 
cells, but not in ovary or fallopian tube epithelial cells. It is possible that the correlation between 
methylation levels of these CpGs and HOXB3 expression are different in ovary epithelial cells 
and white blood cells. For example, in the 5’UTR of HOXB3, a higher methylation at the CpG 
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cg12910797 was significantly associated with an increased EOC risk. The increased methylation 
of this CpG was not correlated with the expression of HOXB3 in white blood cells samples from 
the FHS (Spearman correlation coefficient r=-0.02; P=0.43). Higher methylation of this CpG 
was significantly correlated with a decreased HOXB3 expression in ovarian serous 
cystadenocarcinoma samples from the Cancer Genome Atlas (TCGA) (Spearman correlation 
coefficient r=-0.27; P=2.01×10
-6
) 
(http://gdac.broadinstitute.org/runs/analyses__2016_01_28/reports/cancer/OV-
TP/Correlate_Methylation_vs_mRNA/nozzle.html). 
 
The higher methylation of the CpG site cg17941109, located at the 2
nd
 intron of the ABHD8 gene, 
was associated with a lower ABHD8 expression and a lower EOC risk. This is consistent with the 
results of two recent studies that showed that a higher expression level of this gene was 
associated with an increased risk of EOC (47,48). This gene is located at 19p13.11, a 
susceptibility locus for both ovarian and breast cancers. Interestingly, in our unpublished data, 
the increased genetically predicted methylation level at cg17941109 was associated with 
decreased breast cancer risk, and the genetically predicted expression of ABHD8 was associated 
with an increased breast cancer risk. Increasing evidence also suggests that this protein family 
(ABHD) has a physiological significance in metabolism and disease (49).  
 
For the ARHGAP27 gene, increased methylation of two CpGs in the promoter region, 
cg16281322 and cg25708777, and one CpG in the 3’-UTR, cg07067577, were associated with 
lower expression level of ARHGAP27 and lower EOC risk. For the SKAP1 gene, a higher 
methylation at the CpG cg02957270, located at the promoter region, was associated with a 
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higher expression level and increased EOC risk. Increased methylation of the other intronic CpG, 
cg19139618, was associated with a lower SKAP1 expression and a decreased EOC risk. In the 
present study, the associations of expression levels of these two genes and EOC risk could not be 
investigated because the prediction models for them could not be built. However, two large 
GWAS studies have identified these two genes as EOC susceptibility genes with solid 
experimental evidence (36,37). Differential expression analyses showed a significantly higher 
expression of ARHGAP27 in ovarian cancer than in normal cells (37). It is suggested that the 
ARHGAP27 gene may play a role in carcinogenesis through the dysregulation of 
Rho/Rac/Cdc42-like GTPases (50). The expression of SKAP1 was significantly greater in 
ovarian cancer cells when compared to primary human ovarian surface epithelial cells (36). Our 
study is the first to suggest that these two genes may be associated with EOC risk through 
methylation regulation. 
 
Several epidemiological studies have investigated the associations of CpG methylation and EOC 
risk in white blood cells and tumor tissue samples (12-15). Approximately 100 CpGs have been 
identified to be associated with EOC risk. However, only two CpGs, cg10061138 and 
cg10636246, showed consistent association directions in two or more studies. In the present 
study, prediction models could not be built for these two CpGs; hence, neither could be 
investigated in association with EOC risk. Among the remaining 98 reported CpGs, reliable 
prediction models were built for only 20 of them and only two, cg19399532 and cg21870884, 
could be replicated at P<0.10, with the same association directions as previously reported. Such 
a low replication rate is not unexpected because of several potential limitations in traditional 
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epidemiological studies, which include possible false associations because of small sample size, 
lack of validation in other studies, potential confounders and reverse causation.  
 
The methodology of this study is similar to that of transcriptome-wide association studies 
(TWAS), in which gene expression prediction models are established and applied to GWAS data 
to investigate genetically predicted gene expression in association with various diseases and 
traits. Of the five genes identified in the present study, the expression levels of two, HOXB3 and 
ABHD8, were significantly associated with EOC risk at the Bonferroni-corrected threshold 
(P<2.2×10
-6
) in our previous TWAS study for EOC (51). The MAPT gene showed an association 
with EOC at P=3.74×10-4 in the TWAS, however the association didn’t reach the Bonferroni-
corrected threshold. For ARHGAP27 and SKAP1, gene expression prediction models could not 
be built, and they were not investigated in the TWAS. Expression levels for these two genes 
were reported to be associated with EOC (36,37). Some genes identified in TWAS were not 
tested in the present study because the methylation prediction models could not be built for CpGs 
flanking them. In addition, except DNA methylation, there are other biological processes that 
regulate gene expression. The regulation of DNA methylation on gene expression differs 
according to the locations of the CpGs. Therefore, integrating the results of methylation and gene 
expression analyses may help to understand the biological basis for EOC.  
 
It would be ideal to build methylation prediction models using data from normal ovary or 
fallopian tube epithelial cells, but it is almost impossible to collect tissue samples from a large 
population of healthy women. However, as demonstrated by multiple studies, the large majority 
of the meQTLs identified in white blood cells were consistently detected across different tissue 
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types (26,52,53). These results indicate that the genetically determined methylation at many 
CpGs are predictable and consistent among different tissues. Hence, it is reasonable to build 
methylation prediction models using data from white blood cell samples and then investigate 
predicted DNA methylation in association with EOC. It would be ideal to validate the findings in 
the present study by directly measuring methylation levels in pre-diagnosis blood samples in 
prospective studies to overcome reverse causation; however, the majority of the samples 
included in the present study were collected after cancer diagnosis. It is possible that DNA 
methylation regulation on gene expression differs across tissues. In the present study, data in 
white blood cell samples were used, which is another limitation. In the association analysis of 
predicted gene expression with EOC risk, the models were built using data from a limited sample 
size of GTEx. Thus, the number of genes evaluated in our study was small. More consistent 
associations across methylation, gene expression and EOC risk could be identified with a larger 
sample size to build gene expression prediction models. 
 
Strengths of this study include the large number of samples in the reference dataset used in 
model building and that the model performance was evaluated in an independent dataset. Using 
genetic variants as study instruments, we can effectively overcome many limitations commonly 
encountered in conventional epidemiologic studies. In addition, this is the largest study of DNA 
methylation with EOC risk and a very stringent criterion was used, providing high statistical 
power to identify reliable associations between genetically predicted methylation and EOC risk. 
Finally, the integrative analyses of genetic, DNA methylation and gene expression data led to the 
identification of consistent evidence to support the hypothesis that DNA methylation could 
impact EOC risk through regulating gene expression.  
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In summary, in the largest study conducted to date that investigates DNA methylation in 
association with EOC risk, we identified multiple CpGs that were significantly associated with 
EOC risk and proposed that several CpGs may affect EOC risk through regulating expression of 
five genes. Our study demonstrates the feasibility of integrating multi-omics data to identify 
novel biomarkers for EOC risk and brings new insight into the etiology of this malignancy. 
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Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Two novel methylation-EOC associations for two CpGs located at a genomic region not yet reported for EOC risk 
CpG Chr Position Closest gene Classification RFHS
2 a
 Histotype Z score OR (95% CI) 
b
 P value 
cg18139273 7 962,582 ADAP1 Intronic 0.01 
Overall -4.95 0.51 (0.39-0.66) 7.25×10
-7
 
Serous 
c
 -4.87 0.46 (0.34-0.63) 1.13×10
-6
 
High-grade serous -4.83 0.46 (0.33-0.63) 1.39×10
-6
 
Endometrioid  -1.78 0.59 (0.33-1.06) 0.08 
Mucinous -0.99 0.67 (0.30-1.49) 0.32 
Clear cell -1.87 0.46 (0.21-1.04) 0.06 
Low-grade serous -0.97 0.62 (0.24-1.63) 0.33 
cg03634833 7 965,534 ADAP1 Intronic 0.09 
Overall -5.00 0.84 (0.79-0.90) 5.81×10
-7
 
Serous 
c
 -4.85 0.83 (0.77-0.89) 1.21×10
-6
 
High-grade serous -4.85 0.82 (0.76-0.89) 1.25×10
-6
 
Endometrioid  -2.21 0.83 (0.71-0.98) 0.03 
Mucinous -1.40 0.87 (0.71-1.06) 0.16 
Clear cell -1.76 0.84 (0.69-1.02) 0.08 
Low-grade serous -0.87 0.91 (0.73-1.13) 0.39 
a
 Correlation between predicted and measured methylation levels.                                                                                                                   
b
 OR, odds ratio per standard deviation increase in genetically predicted methylation level; CI, confidence interval.                                                                                                               
c 
Including high-grade serous and low-grade serous ovarian cancers. 
Table 2. Selected 
a
 seven methylation-EOC associations driven by previously identified EOC risk SNPs 
CpG Chr Position Closest gene Classification Z score OR (95% CI) 
b
 P value RFHS
2 c
 EOC risk SNPs  
Distance to the 
risk SNPs (kb) 
P value adjusted 
for the risk SNPs 
cg25137403 2 177,022,172 HOXD4; HOXD3 Intergenic 7.51 1.24 (1.18-1.32) 5.96×10
-14
 0.15 rs6755777; rs711830 21;15 0.09 
cg26405475 3 156,324,038 SSR3; TIPARP-AS1 Intergenic -9.45 0.69 (0.64-0.74) 3.42×10
-21
 0.07 rs62274041 111 0.34 
cg08478672 8 129,374,295 MIR1208; LINC00824 Intergenic 5.08 1.29 (1.17-1.42) 3.81×10
-7
 0.06 rs1400482 167 0.05 
cg14653977 9 136,038,692 GBGT1 Intronic 5.99 1.75 (1.46-2.09) 2.04×10
-9
 0.03 9:136138765 
d
 100 0.09 
cg04231319 10 21,824,447 MLLT10 Intronic -5.72 0.88 (0.84-0.92) 1.05×10
-8
 0.19 rs144962376 54 0.94 
cg07067577 17 43,506,829 ARHGAP27 3'UTR -7.49 0.73 (0.67-0.79) 6.86×10
-14
 0.07 rs1879586 60 0.01 
cg21956434 19 17,377,697 BABAM1 TSS1500 7.07 1.13 (1.09-1.17) 1.53×10
-12
 0.34 rs4808075 12 0.39 
a
 Selected from 87 CpG-EOC associations. For each locus, only the most significantly associated CpG was presented.
  
Complete list of results for all CpG-EOC associations is available in 
Supplementary Table 1.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
b
 OR, odds ratio per standard deviation increase in genetically predicted methylation level; CI, confidence interval.                                                                                                                                                                                                                            
c
 Correlation between predicted and measured methylation levels.                                                                                                                                                                                                                            
d
 GRCh37 position. 
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Table 3. Selected 
a
 correlations between methylation levels at 26 CpGs and 
expression levels of 12 genes, data from the Framingham Heart Study 
CpG Chr Position Classification Closest gene Rho P value 
cg25137403 2 177,022,172 Downstream HOXD4 -0.06 0.02 
cg22211092 3 156,361,584 Downstream SSR3 0.09 9.43×10
-4
 
cg03634833 7 965,534 Intronic ADAP1 -0.08 2.99×10
-3
 
cg14653977 9 136,038,692 Intronic GBGT1 -0.06 0.02 
cg24267699 9 136,151,359 TSS1500 ABO -0.09 8.07×10
-4
 
cg10900703 10 21,824,407 Intronic MLLT10 0.18 2.79×10
-11
 
cg23659289 17 43,472,725 3'UTR ARHGAP27 -0.19 9.89×10
-13
 
cg07368061 17 44,090,862 Intronic MAPT 0.08 2.02×10
-3
 
cg19139618 17 46,504,791 Intronic SKAP1 -0.21 2.98×10
-15
 
cg14285150 17 46,659,019 Intronic HOXB3 0.11 8.44×10
-5
 
cg22311200 17 46,695,514 Downstream HOXB8 0.08 2.59×10
-3
 
cg17941109 19 17,407,198 Intronic ABHD8 -0.06 0.03 
a
 Selected from correlations between 26 CpGs and 12 genes. For each gene, only the 
most significantly correlated CpG was presented. Complete list of results for all CpG-
EOC associations is available in Supplementary Table 6.         
Table 4. Three genes with genetically predicted expression levels associated 
with EOC risk 
Region Gene Type Z score P value Adjusted 
a
 P value R
2 b
 
17q21.31 MAPT Protein -3.56 3.74×10
-4
 0.40 0.08 
17q21.32 HOXB3 Protein -5.20 2.00×10
-7
 0.71 0.12 
19p13.11 ABHD8 Protein 4.42 9.93×10
-6
 0.59 0.23 
a
 Adjusting for the EOC risk SNPs in the corresponding locus.                                                                                               
b
 Correlation between predicted and measured gene expression levels.                                                            
Table 5. Consistent directions of associations across CpG methylation, gene expression and EOC risk for 12 CpGs and five genes 
CpG Chr Position Gene Classification 
CpG Vs. EOC risk CpG Vs. Gex 
b
 Gex 
b 
Vs. EOC risk 
Adjusted 
a
 Gex 
Vs. EOC risk  
Dir 
b
 P value Dir 
b
 P value Dir 
b
 P value Dir P value 
cg18878992 17 43,974,344 MAPT 5'UTR + 8.85×10
-13
 - 2.64×10
-3
 - 3.74×10
-4
 - 0.48 
cg00480298 17 44,068,857 MAPT Exonic + 6.39×10
-9
 - 3.98×10
-3
 - 3.74×10
-4
 - 0.65 
cg07368061 17 44,090,862 MAPT Intronic - 4.26×10
-13
 + 2.02×10
-3
 - 3.74×10
-4
 - 1.00 
cg01572694 17 46,657,555 HOXB3 Intronic - 5.52×10
-9
 + 7.49×10
-3
 - 2.00×10
-7
 - 0.82 
cg14285150 17 46,659,019 HOXB3 Intronic - 5.53×10
-8
 + 8.44×10
-5
 - 2.00×10
-7
 - 0.51 
cg24672833 17 46,659,318 HOXB3 Intronic - 9.00×10
-8
 + 5.51×10
-3
 - 2.00×10
-7
 - 0.41 
cg17941109 19 17,407,198 ABHD8 Intronic - 2.88×10
-9
 - 0.03 + 9.93×10
-6
 - 0.57 
cg19139618 17 46,504,791 SKAP1 Intronic - 7.08×10
-7
 - 2.98×10
-15
 + 
NA 
c
 
cg02957270 17 46,508,097 SKAP1 TSS1500 + 4.40×10
-12
 + 0.01 + 
cg07067577 17 43,506,829 ARHGAP27 3'UTR - 6.86×10
-14
 - 1.20×10
-3
 + 
NA 
c
 cg16281322 17 43,510,478 ARHGAP27 TSS200 - 6.82×10
-13
 - 1.14×10
-9
 + 
cg25708777 17 43,510,841 ARHGAP27 TSS1500 - 4.61×10
-13
 - 4.11×10
-8
 + 
a
 Adjusting for all the predicting SNPs included in prediction models of corresponding CpGs                                                                                                                 
b
 Dir, direction of association/correlation; Gex, gene expression                                                                                                                                                                       
c
 SKAP1 and ARHGAP27 are previously identified EOC-susceptibility genes.                                                                                                                                                                                                                                                      
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Figure legends 
Figure 1. Study design flow chart 
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